Carcinotech

Carcinotech, founded in 2018 and based in Edinburgh, is a preclinical contract research organization (CRO) specializing in advanced 3D-bioprinted tumor models for oncology research. The company's core offering is its Carcino3D™ platform, which creates assay-ready, patient-derived models incorporating multiple cell types to better mimic the in vivo tumor microenvironment. By providing these models and associated testing services, Carcinotech aims to bridge resource gaps for drug developers, increase the predictive accuracy of preclinical testing, and ultimately improve clinical trial success rates and personalized therapy decisions. Its services support a wide range of therapeutic modalities, from immunotherapies to chemotherapies.

Proprietary 3D bioprinting platform (Carcino3D™) for creating patient-derived, assay-ready tumor models that incorporate multiple cell types to replicate the native tumor microenvironment.

Carcinotech competes in the crowded market for advanced preclinical models, which includes companies offering organoid, spheroid, and other 3D culture technologies, as well as other bioprinting specialists. It also competes with larger, full-service CROs that may develop similar capabilities in-house. Its differentiation lies in its specific focus on 3D-bioprinted, patient-derived solid tumor models and an end-to-end service offering.